BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: SICKLE CELL DISEASE, GENE THERAPY

BD BIOSCIENCES FACS CANTO 流式细胞仪：镰状细胞病，基因治疗

• 批准号: 7335105
• 负责人: LAWRENCE S LAMB
• 金额: $ 1.75万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7335105
• 关键词: AIDS; gene therapy; neoplasm /cancer; sickle cell anemia; university

This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): This application requests funds to purchase the BD Biosciences FACS Canto flow cytometer for the Laboratory for Cellular and Tissue Engineering (LCTE) at the University of Alabama at Birmingham. The instrument will be used to replace a 12 year old BD Biosciences FACS Sort cytometer that has required frequent servicing that at times has impacted the functioning of the laboratory. This instrumentation will allow the laboratory to continue to serve its users well into the future and to expand functionality to allow six-color flow cytometry. The LCTE is a CLIA, CAP, and FACT-compliant core facility supported by the Comprehensive Cancer Center, the Center for AIDS Research, and the Sickle Cell Center. The LCTE provides a platform for translation of promising cellular therapy (including gene-modified cellular therapy) protocols for UAB investigators. The facility provides support from the earliest level of preclinical development to the preparation of clinical grade materials and submission of INDs. Many cell products that are generated in the LCTE are prepared in a clean room environment. The current flow cytometer is located in an adjacent laboratory with a pass-through to the clean suites allowing immediate on-site analysis and consultation with the team that is preparing the graft. Since the graft engineering work often requires multiple steps with flow cytometric analysis required prior to critical decisions during processing, transport of the specimens to another facility for analysis would unnecessarily prolong the processing and potentially compromise the product. In addition, when the LCTE cytometer is not being used for cellular graft evaluation, it is available for overflow work from the Comprehensive Cancer Center, Center for AIDS Research, and the Brain Tumor SPORE NIH-funded investigators that require a 51 OK approved instrument in a CLIA-approved laboratory for their protocols. The Principal Investigator has recently been funded by the University of Alabama Health Services Foundation to undertake a major expansion of the LCTE to include protocols for somatic cell therapy, myocardial regeneration, gene therapy for sickle cell disease, dendritic cell and regulatory cell therapy for autoimmune disorders, and bone regeneration. These protocols, in addition to existing hematopoietic cell therapy and immunotherapy trials nearing approval, will substantially increase the number of users over the next two years. The laboratory will require an instrument that will serve the laboratory in the development and execution of advanced cell therapy trials.

该副本是利用NIH/NCRR资助的共享仪器赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构是赠款，这不一定是调查人员的机构。描述（由申请人提供）：本申请要求资金购买BISCIENCES FACS CANTO流式细胞仪，用于伯明翰阿拉巴马大学的蜂窝和组织工程实验室（LCTE）。该仪器将用于替换12岁的BD Biosciences FACS排序细胞仪，该仪需要经常进行维修，这有时会影响实验室的功能。该仪器将使实验室能够继续为未来的用户提供良好的服务，并扩大功能，以允许六色流式细胞仪。 LCTE是由综合癌症中心，艾滋病研究中心和镰状细胞中心支持的CLIA，CAP和符合事实的核心设施。 LCTE为UAB研究者提供了有希望的细胞疗法（包括基因改性的细胞疗法）方案的平台。该设施提供了最早的临床前开发水平的支持，到制备临床等级材料和提交INDS的支持。 LCTE中生成的许多细胞产品都在洁净室环境中制备。当前的流式细胞仪位于相邻的实验室中，并通过通往干净的套房进行通行，从而可以立即进行现场分析并与准备移植物的团队进行咨询。由于移植工程工作通常需要多个步骤，并在处理过程中需要进行批判性决策之前需要进行流式细胞仪分析，因此将样品运输到另一个设施进行分析将不必要地延长处理并可能损害产品。此外，当LCTE细胞仪不用于细胞移植评估时，它可用于综合癌症中心，艾滋病研究中心和脑肿瘤孢子NIH资助的研究人员的溢出工作，该研究人员需要在CLIA批准的实验室中获得51个OK批准的工具，以便其协议。首席研究员最近由阿拉巴马大学卫生服务基金会资助，以进行LCTE的重大扩展，包括用于体细胞疗法的方案，心肌再生，镰状细胞病的基因治疗，树突状细胞和调节性细胞治疗，用于自身免疫性疾病以及骨骼再生。除了现有的造血细胞疗法和接近批准的免疫疗法试验外，这些方案还将大大增加未来两年的使用者数量。该实验室将需要一种工具，该工具将在开发和执行晚期细胞治疗试验中为实验室服务。